Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal

Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6% weight loss in Phase 3.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Erasca, ERAS-0015, pan-RAS, KRAS, AbbVie, Kestrel Therapeutics, Eli Lilly, Ajax Therapeutics, JAKinhibitor, myelofibrosis, Amgen, Tavneos, ChemoCentryx, data manipulation, Intellia Therapeutics, CRISPR, gene editing, BridgeBio, Vyndamax, Pfizer, Boehringer Ingelheim, survodutide, obesity, AstraZeneca, Breztri, asthma,Incyte, vitiligo, Oruka, psoriasis, Veradermics, Sanofi, tolebrutinib, Lilly